The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01
Brain Tumor Research and Treatment
; : 74-84, 2019.
Article
在 En
| WPRIM
| ID: wpr-763111
Responsible library:
WPRO
ABSTRACT
BACKGROUND:
There was no practical guideline for the management of patients with central nervous system tumor in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, has developed the guideline for glioblastoma. Subsequently, the KSNO guideline for World Health Organization (WHO) grade II cerebral glioma in adults is established.METHODS:
The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified by searching PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords regarding diffuse astrocytoma and oligodendroglioma of brain in adults.RESULTS:
Whenever radiological feature suggests lower grade glioma, the maximal safe resection if feasible is recommended globally. After molecular and histological examinations, patients with diffuse astrocytoma, isocitrate dehydrogenase (IDH)-wildtype without molecular feature of glioblastoma should be primarily treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy (Level III) while those with molecular feature of glioblastoma should be treated following the protocol for glioblastomas. In terms of patients with diffuse astrocytoma, IDH-mutant and oligodendroglioma (IDH-mutant and 1p19q codeletion), standard brain radiotherapy and adjuvant PCV (procarbazine+lomustine+vincristine) combination chemotherapy should be considered primarily for the high-risk group while observation with regular follow up should be considered for the low-risk group.CONCLUSION:
The KSNO's guideline recommends that WHO grade II gliomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to molecular and histological features of tumors and clinical characteristics of patients.Key words
全文:
1
索引:
WPRIM
主要主题:
Oligodendroglioma
/
Radiotherapy
/
Astrocytoma
/
World Health Organization
/
Brain
/
Central Nervous System
/
Follow-Up Studies
/
Glioblastoma
/
Drug Therapy
/
Drug Therapy, Combination
研究类型:
Guideline
/
Observational_studies
/
Prognostic_studies
限制:
Adult
/
Humans
国家/地区名称主题:
Asia
语言:
En
期刊:
Brain Tumor Research and Treatment
年:
2019
类型:
Article